Table 2.
Major clinical trials on nivolumab and pembrolizumab for treatment of Hodgkin lymphoma
| Study | Trial name | Phase | N | Setting | Treatment | Efficacy results |
|---|---|---|---|---|---|---|
| Ansell et al. 2015 [52] | CheckMate 039 (arm 1, expansion cohort) | 1 | 23 | Relapsed or refractory | Nivolumab 3 mg/kg Q2W for up to 2 years | ORR 87% (CR 17%, PR 70%) PFS rate at 24 weeks 86% |
| Younes et al. 2016 [54–56] | CheckMate 205 (cohort B) | 2 | 80 | Relapsed or refractory after ASCT and brentuximab vedotin | Nivolumab 3 mg/kg Q2W | ORR 68% (CR 13%, PR 55%) 12-month PFS rate 54.6%, OS rate 94.9% Median PFS 14.7 months |
| Armand et al. 2018 [56] | CheckMate 205 (cohorts A and C) | 2 | Cohort A: 63 Cohort C: 100 |
Cohort A: relapsed or refractory, brentuximab vedotin naïve Cohort C: relapsed or refractory after brentuximab vedotin |
Nivolumab 3 mg/kg Q2W | Cohort A: ORR 65% (CR 29%) Median DOR 20.3 months Median PFS 18.3 months Cohort C: ORR 73% (CR 12%) Median DOR 14.5 months Median PFS 11.9 months |
| Herbaux et al. 2017 [58] | 20 | Relapsed after Allo-SCT | Nivolumab 3 mg/kg Q2W | ORR 95% (CR 42%, PR 52%) 1-year PFS rate 58.2%, OS rate 78.7% |
||
| Ramchandren et al. 2017 [59] | CheckMate 205 (cohort D) | 2 | 51 | Newly diagnosed advanced stage | Nivolumab 240 mg biweekly for 4 doses, followed by nivolumab plus AVD for 6 cycles | ORR 84% (CR 80%, PR 4%) Modified PFS rate at 9 months 94% |
| Ansell et al. 2016 [60] | CheckMate 039 (arm 2) | 1 | 31 | Relapsed or refractory | Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W for 4 cycles, followed by nivolumab 3 mg/kg Q2W for up to 2 years | ORR 74% (CR 19%, PR 55%) |
| Herrera et al. 2017 [62] | 1/2 | 62 | Relapsed after or refractory to frontline therapy | Nivolumab 3 mg/kg plus brentuximab vedotin 1.8 mg/kg Q3W for up to 4 cycles | ORR 83% (CR 62%) | |
| Armand et al. 2016 [63, 64] | KEYNOTE-013 | 1b | 31 | Relapsed or refractory after brentuximab vedotin | Pembrolizumab 10 mg/kg Q2W for up to 2 years | ORR 65% (CR 16%, PR 48%) median PFS 11.4 months 6-month PFS rate 66%, OS rate 100% 12-month PFS rate 48%, OS rate 87% |
| Chen et al. 2017 [65] | KEYNOTE-087 | 2 | 210 | Relapsed or refractory after ASCT and/or brentuximab vedotin | Pembrolizumab 200 mg Q3W for up to 2 years | ORR 69.0% (CR 22.4%, PR 46.7%) 6-month PFS rate 72.4%, OS rate 99.5% 9-month PFS rate 63.4%, OS rate 97.5% |
N patient number, Q2W every 2 weeks, Q3W every 3 weeks, AVD adriamycin, vinblastine, dacarbazine, ASCT autologous stem cell transplantation, ORR objective response rate, CR complete response, PR partial response, PFS progression-free survival, OS overall survival